Theriva Biologics (TOVX) news
Recent news
THERIVA BIOLOGICS Q2 EPS USD -0.07
Theriva Biologics Inc. (TOVX) reported earnings per share (EPS) of -$0.07 for the second quarter of 2026, according to recent financial updates. This figure reflects the company’s continued financial challenges as it operates in the clinical-stage biopharmaceutical sector. The reported EPS of…
AInvest Wire · Aug 11, 2026ImportantTheriva Biologics shares up 22% premarket after receives notice of allowance for US patent application titled "beta-lactamase formulations & uses thereof"
Theriva Biologics shares up 22% premarket after receives notice of allowance for US patent application titled "beta-lactamase formulations & uses thereof" Theriva Biologics Inc. (TOVX) experienced a significant pre-market surge on Wednesday, June 28, 2023, following the news that the US Patent and…
AInvest Wire · Aug 29, 2024ImportantTheriva Biologics announced new clinical data from Phase 1 investigator-sponsored study with Institut Catala d’oncologia evaluating VCN-01 in combination with durvalumab
AInvest Wire · Oct 23, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.